SeaSpine Holdings Corporation (NASDAQ:SPNE) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SPNE is expected to report 3Q20 loss of $ 0.31 per share from revenue of $ 41.96 million.
For the full year, analysts anticipate top line of $ 153.05 million, while looking forward to loss of $ 1.5 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 42.90 million ~ $ 43.30 million
Full Year 2020 topline are forecasted in a range of$ 177.00 million ~ $ 181.00 million
Click Here For More Historical Outlooks Of SeaSpine Holdings Corporation
Previous Quarter Performance
SeaSpine Holdings Corporation unfold loss for the second quarter of $ 0.50 per share, from the revenue of $ 28.59 million. The quarterly revenues reduced 27.27 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.74 per share from $ 19.44 million in revenue. The bottom line results beat street analysts by $ 0.24 or 32.43 percent, at the same time, top line results outshined analysts by $ 9.15 million or 47.07 percent.
Stock Performance
On Friday, shares of SeaSpine Holdings Corporation has traded high as $ 13.87 and has cracked $ 13.14 on the downward trend, reaching $ 13.66 with volume of 101.90 thousand shares.
According to the previous trading day, closing price of $ 13.66, representing a 239.80 % increase from the 52 week low of $ 4.02 and a 19.22 % decrease over the 52 week high of $ 16.91.
The company has a market capital of $ 376.98 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
SeaSpine Holdings Corporation will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.seaspine.com
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.
